South Korea has agreed to purchase 70,000 programs of Pfizer Inc’s experimental antiviral COVID-19 tablet, the Korea Disease Control and Prevention Agency (KDCA) stated on Saturday.
Pfizer on Friday stated trial outcomes confirmed that its Paxlovid tablet diminished by 89% the chance of hospitalization or loss of life in sufferers at excessive danger of extreme sickness inside three days of the onset of coronavirus signs.
South Korea has already signed agreements to safe 200,000 programs of Merck & Co Inc’s COVID-19 therapy. It is trying to purchase a further 134,000 programs, although it’s undecided of which therapy, KDCA stated.
Last month, the federal government stated it was in talks with Swiss pharmaceutical Roche Holding AG, which is creating an easy-to-administer antiviral tablet for COVID-19.
The authorities had allotted a price range of 36.2 billion gained ($30.63 million) for oral COVID-19 antiviral tablets.
Pfizer is in talks with 90 international locations over provide contracts for Paxlovid, Chief Executive Officer Albert Bourla stated in an interview on Friday.
The UK has already secured 480,000 programs of Merck’s drug and procured 250,000 programs of the Pfizer therapy.
This story has been printed from a wire company feed with out modifications to the textual content. Only the headline has been modified.
Never miss a narrative! Stay related and knowledgeable with Mint.
our App Now!!